Just presented at ARVO: Suprachoroidal CLS-AX (axitinib injectable suspension)…
[ad_1]
Just presented at ARVO:
Suprachoroidal CLS-AX (axitinib injectable suspension), as a Potential Long-Acting Therapy for Neovascular Age-Related Macular Degeneration (nAMD) | IOVS | ARVO Journals https://t.co/OigBzx215J
#retina #eyes #ophthalmology #ophthalmologist #optometry https://t.co/WWv4RJYvGk
[ad_2]
Source by Thomas Ciulla, MD, MBA